Allen Capital Group LLC Purchases 9,904 Shares of Zoetis Inc. $ZTS

Allen Capital Group LLC lifted its position in shares of Zoetis Inc. (NYSE:ZTS) by 35.0% in the fourth quarter, HoldingsChannel reports. The fund owned 38,177 shares of the company’s stock after buying an additional 9,904 shares during the period. Allen Capital Group LLC’s holdings in Zoetis were worth $4,803,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Nordea Investment Management AB increased its holdings in Zoetis by 79.2% in the fourth quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares during the last quarter. CIBC Asset Management Inc increased its holdings in Zoetis by 4.3% in the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock valued at $36,745,000 after purchasing an additional 10,434 shares during the last quarter. Seilern Investment Management Ltd increased its holdings in Zoetis by 361.2% in the fourth quarter. Seilern Investment Management Ltd now owns 333,465 shares of the company’s stock valued at $41,957,000 after purchasing an additional 261,155 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in Zoetis by 134.4% in the fourth quarter. Assenagon Asset Management S.A. now owns 1,631,619 shares of the company’s stock valued at $205,290,000 after purchasing an additional 935,432 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp increased its holdings in Zoetis by 6.5% in the third quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock valued at $43,235,000 after purchasing an additional 18,040 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.1%

ZTS stock opened at $81.26 on Monday. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The stock has a market capitalization of $34.06 billion, a P/E ratio of 13.48, a P/E/G ratio of 1.33 and a beta of 0.87. The business has a 50-day moving average of $108.11 and a 200-day moving average of $118.47. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). The firm had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm’s quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be given a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is currently 35.16%.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the company. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a report on Tuesday, March 10th. UBS Group dropped their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Monday, March 2nd. Finally, Citigroup decreased their target price on Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Zoetis has a consensus rating of “Hold” and an average price target of $133.92.

Insider Transactions at Zoetis

In other news, Director Paul Bisaro acquired 2,000 shares of Zoetis stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the transaction, the director directly owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This represents a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the transaction, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This trade represents a 13.94% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 11,650 shares of company stock valued at $886,384 over the last three months. Company insiders own 0.22% of the company’s stock.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.